May. 18, 2020
The changes in this bulletin apply to all groups that use the Net Cost Formulary.
Apr. 02, 2020
The FDA announced that it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately due to contamination with N-Nitrosodimethylamine (NDMA).
Mar. 05, 2020
As a part of our PBM’s strategy for battling the national opioid epidemic, effective March 1, 2020, home delivery through OptumRx will require e-prescriptions for ALL controlled substances [for example, opioids for pain, stimulant drugs used to treat Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)].
Feb. 28, 2020
The FDA announced the request to voluntarily withdraw Belviq, Belviq XR (lorcaserin) from the U.S. market because a safety clinical trial showed an increased occurrence of cancer.
Sep. 04, 2019
We are taking steps to ensure our members’ health care coverage needs are continuous and flexible in the event of a storm.
Jul. 08, 2019
PAI is making some adjustments to our prescription drug lists and pharmacy programs as part of our continued effort to cover medications that are appropriate, as well as cost-effective, for members.
May. 01, 2019
These updates apply to PAI groups that use the Caremark Preferred Drug List.
Jan. 16, 2019
These updates apply to PAI groups that use the Caremark Preferred Drug List.
Dec. 27, 2018
Beginning January 1, 2019, we will add Triamcinolone spray to our Quantity Management program. This applies to PAI's self-funded groups that use the Caremark Preferred Drug List.
Oct. 15, 2018
The changes in this bulletin go into effect January 1, 2019, unless noted otherwise. They apply to PAI groups that use the Caremark Preferred Drug List.